Avalo Therapeutics, Inc.
AVTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$6.75
KIRA · Stoqly’s AI analyst, in plain words
- Avalo Therapeutics, Inc. had $0.1M of revenue in fiscal 2025, down 86.6% on the year before. Over five years, revenue changed −61.2% a year on average.
- Its operating margin was −123,601.7%, down 108,066.1 pts: of every 100 in sales, about −123,602 is left after running the business.
- Avalo Therapeutics, Inc. lost $78.3M in fiscal 2025.
Market cap
$294M
P/E
—
Revenue
$0.1M
Net income
−$78.3M
Free cash flow
—
Operating margin
−123,601.7%
Avalo Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−86.6%
No. Sales fell 86.6% last year.
Does it make a profit?
−132,642.4%
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Avalo Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 23, 2026
- Legal name
- Avalo Therapeutics, Inc.
- CIK
- 0001534120
Avalo Therapeutics, Inc. · AVTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $5.4M | $18.1M | $1.9M | $0.4M | $0.1M |
| Revenue growth | −19.4% | 234.4% | −89.3% | −77.1% | −86.6% |
| Gross margin | 72.4% | 81.0% | 33.3% | — | — |
| Operating margin | −1,521.6% | −207.4% | −1,421.6% | −15,535.6% | −123,601.7% |
| Net income | −$84.4M | −$41.7M | −$31.5M | −$35.1M | −$78.3M |
| Net margin | −1,563.1% | −230.8% | −1,639.5% | −7,965.8% | −132,642.4% |
| Diluted EPS | — | −$1,063.00 | −$113.58 | −$20.91 | −$5.84 |
| Cash | |||||
| Cash from operations | −$70.9M | −$26.8M | −$30.7M | −$49.1M | −$51.5M |
| Capital expenditure | $0.1M | $0.1M | — | — | — |
| Free cash flow | −$71.0M | −$26.8M | — | — | — |
| FCF margin | −1,315.4% | −148.7% | — | — | — |
| Share count change | — | — | 608.4% | 2,599.5% | 78.8% |
| Debt and strength | |||||
| Cash and short-term investments | $54.6M | $13.2M | $7.4M | $135M | $98.3M |
| Shareholders' equity | $23.1M | −$10.9M | $7.3M | $133M | $83.0M |
| Current ratio | 3.1x | 0.7x | 1.8x | 20.0x | 8.1x |
| Returns and quality | |||||
| Return on equity | −354.2% | −684.8% | — | −50.1% | −72.4% |
| Return on tangible equity | −977.1% | — | — | −28.7% | −107.9% |
| Piotroski F-score | 3 | 3 | 2 | 2 | 1 |
| Altman Z'' | −13.7 | −38.6 | −59.1 | 2.6 | −9.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$8.5M
6 insiders
Of sales under plans
97%
$8.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Avalo Therapeutics, Inc. · AVTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.75 a share, the company is worth $294M.
Source: SEC EDGAR XBRL filings (CIK 0001534120). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.